CCN4

Across TCGA pan-cancer cohorts, CCN4 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CCN4 data layer compared with 27 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CCN4 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CCN4 expression acts as an unfavorable survival marker, although some lineages such as GBM and LUAD show a favorable association.

PDAC, GBM, and LUAD are the cancer types where CCN4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.337	0.753	.003	23	view →
GBM	DFS	Quartile	All	0.821	0.283	.004	10	view →
LUAD	DFS	Median	II,III,IV	0.888	0.196	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CCN4–PDAC (OS)

Open the PDAC breakdown →